Experience of using Relatox in the complex rehabilitation of patients with lower limb spasticity after focal brain damage of various etiologies

OBJECTIVE: Evaluating the safety and efficacy of Relatox, a Russian botulinum neuroprotein type A preparation, in the comprehensive rehabilitation of patients with focal and multipattern lower limb spasticity due to focal brain damage of various etiologies (stroke, traumatic brain injury, neurosurgical interventions). MATERIAL AND METHODS: The prospective study included 15 patients with spasticity scores ≥2 on the modified Ashworth Spinal Scale. Under dual navigation guidance (ultrasound and electromyography), Relatox injections were administered to the lower limb muscles at doses of up to 400 U. Five patients with multipattern spasticity also received injections to the upper limb muscles at a maximum dose of up to 800 U. Efficacy assessments were conducted at weeks 4 and 12. RESULTS: Results showed a decrease in muscle tone, a significant increase in walking speed, and improvement in walking parameters. The safety profile of the drug was favorable: four adverse events were recorded (one case of generalized weakness at a dose of 800 U and three localized hematomas), and no serious adverse events were observed. CONCLUSION: The authors conclude that Relatox has proven efficacy and safety for the treatment of lower limb spasticity, including the use of high doses in multipattern lesions. The drug reduces muscle tone, increases range of motion, and improves functional gait, justifying its inclusion in standard rehabilitation programs. Further studies with a larger number of patients are needed to optimize treatment protocols, determine optimal doses, and determine long-term effects.